It has become clearthat special attention should be focused on the activation of interleukin-2 inthe presence of additives: for example, mildronate, arginine, and glutamate.Combined use of these drugs could open new possibilities in the treatment ofserious diseases. The gene discussed is IL2; the disease is glycogen storage disease VI.